Plant Name: Indigofera linnaei
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| CXCR1; NPSR1; | |
| DRD4; | |
| TDP1; CTDSP1; RECQL; PLA2G1B; PIK3R1; GLO1; HPGD; MPO; HSD17B1; HSD17B2; AKR1B1; ALOX15; ALOX12; NOX4; ALDH1A1; HSD17B10; PYGL; POLB; | |
| DAPK1; AKT1; AXL; FLT3; NEK6; PKN1; CDK1; PIM1; CAMK2B; MET; NUAK1; NEK2; KDR; GSK3B; SRC; IGF1R; AURKB; PTK2; ALK; CSNK2A1; | |
| CA2; CA12; CA13; CA9; CA5B; CA1; CA5A; CA3; CA7; CA4; CA6; CA14; | |
| AR; | |
| ESRRA; | |
| ALOX5; TYR; MAOA; XDH; | |
| KDM4E; | |
| MMP9; MMP3; MMP13; MMP2; | |
| BACE1; | |
| AHR; HIF1A; TP53; NFKB1; STAT6; | |
| FUT7; | |
| ABCG2; ABCC1; | |
| LMNA; MAPT; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Aspartic protease | BACE1 | Beta-secretase 1 | P56817 | CHEMBL4822 |
| ATP-binding cassette | ABCG2 | ATP-binding cassette sub-family G member 2 | Q9UNQ0 | CHEMBL5393 |
| ATP-binding cassette | ABCC1 | Multidrug resistance-associated protein 1 | P33527 | CHEMBL3004 |
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
| Cytochrome P450 family 2 | CYP2C8 | Cytochrome P450 2C8 | P10632 | CHEMBL3721 |
| Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
| Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Enzyme_unclassified | GLO1 | Glyoxalase I | Q04760 | CHEMBL2424 |
| Enzyme_unclassified | HPGD | 15-hydroxyprostaglandin dehydrogenase [NAD+] | P15428 | CHEMBL1293255 |
| Enzyme_unclassified | MPO | Myeloperoxidase | P05164 | CHEMBL2439 |
| Enzyme_unclassified | HSD17B1 | Estradiol 17-beta-dehydrogenase 1 | P14061 | CHEMBL3181 |
| Enzyme_unclassified | HSD17B2 | Estradiol 17-beta-dehydrogenase 2 | P37059 | CHEMBL2789 |
| Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
| Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
| Enzyme_unclassified | ALOX12 | Arachidonate 12-lipoxygenase | P18054 | CHEMBL3687 |
| Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
| Enzyme_unclassified | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P00352 | CHEMBL3577 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Enzyme_unclassified | PYGL | Liver glycogen phosphorylase | P06737 | CHEMBL2568 |
| Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | CTDSP1 | Carboxy-terminal domain RNA polymerase II polypeptide A small phosphatase 1 | Q9GZU7 | CHEMBL1795098 |
| Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
| Enzyme_unclassified | PLA2G1B | Phospholipase A2 group 1B | P04054 | CHEMBL4426 |
| Enzyme_unclassified | PIK3R1 | PI3-kinase p85-alpha subunit | P27986 | CHEMBL2506 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA13 | Carbonic anhydrase XIII | Q8N1Q1 | CHEMBL3912 |
| Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
| Lyase | CA5B | Carbonic anhydrase VB | Q9Y2D0 | CHEMBL3969 |
| Lyase | CA1 | Carbonic anhydrase I | P00915 | CHEMBL261 |
| Lyase | CA5A | Carbonic anhydrase VA | P35218 | CHEMBL4789 |
| Lyase | CA3 | Carbonic anhydrase III | P07451 | CHEMBL2885 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Lyase | CA6 | Carbonic anhydrase VI | P23280 | CHEMBL3025 |
| Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
| Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
| Metallo protease | MMP9 | Matrix metalloproteinase 9 | P14780 | CHEMBL321 |
| Metallo protease | MMP3 | Matrix metalloproteinase 3 | P08254 | CHEMBL283 |
| Metallo protease | MMP13 | Matrix metalloproteinase 13 | P45452 | CHEMBL280 |
| Metallo protease | MMP2 | Matrix metalloproteinase-2 | P08253 | CHEMBL333 |
| Nuclear hormone receptor subfamily 3 group B | ESRRA | Estrogen-related receptor alpha | P11474 | CHEMBL3429 |
| Nuclear hormone receptor subfamily 3 group C | AR | Androgen Receptor | P10275 | CHEMBL1871 |
| Oxidoreductase | ALOX5 | Arachidonate 5-lipoxygenase | P09917 | CHEMBL215 |
| Oxidoreductase | TYR | Tyrosinase | P14679 | CHEMBL1973 |
| Oxidoreductase | MAOA | Monoamine oxidase A | P21397 | CHEMBL1951 |
| Oxidoreductase | XDH | Xanthine dehydrogenase | P47989 | CHEMBL1929 |
| Peptide receptor (family A GPCR) | CXCR1 | Interleukin-8 receptor A | P25024 | CHEMBL4029 |
| Peptide receptor (family A GPCR) | NPSR1 | Neuropeptide S receptor | Q6W5P4 | CHEMBL5162 |
| Protein Kinase | CSNK2A1 | Casein kinase II alpha | P68400 | CHEMBL3629 |
| Protein Kinase | DAPK1 | Death-associated protein kinase 1 | P53355 | CHEMBL2558 |
| Protein Kinase | AKT1 | Serine/threonine-protein kinase AKT | P31749 | CHEMBL4282 |
| Protein Kinase | AXL | Tyrosine-protein kinase receptor UFO | P30530 | CHEMBL4895 |
| Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
| Protein Kinase | NEK6 | Serine/threonine-protein kinase NEK6 | Q9HC98 | CHEMBL4309 |
| Protein Kinase | PKN1 | Protein kinase N1 | Q16512 | CHEMBL3384 |
| Protein Kinase | CDK1 | Cyclin-dependent kinase 1 | P06493 | CHEMBL308 |
| Protein Kinase | PIM1 | Serine/threonine-protein kinase PIM1 | P11309 | CHEMBL2147 |
| Protein Kinase | CAMK2B | CaM kinase II beta | Q13554 | CHEMBL4121 |
| Protein Kinase | MET | Hepatocyte growth factor receptor | P08581 | CHEMBL3717 |
| Protein Kinase | NUAK1 | NUAK family SNF1-like kinase 1 | O60285 | CHEMBL5784 |
| Protein Kinase | NEK2 | Serine/threonine-protein kinase NEK2 | P51955 | CHEMBL3835 |
| Protein Kinase | KDR | Vascular endothelial growth factor receptor 2 | P35968 | CHEMBL279 |
| Protein Kinase | GSK3B | Glycogen synthase kinase-3 beta | P49841 | CHEMBL262 |
| Protein Kinase | SRC | Tyrosine-protein kinase SRC | P12931 | CHEMBL267 |
| Protein Kinase | IGF1R | Insulin-like growth factor I receptor | P08069 | CHEMBL1957 |
| Protein Kinase | AURKB | Serine/threonine-protein kinase Aurora-B | Q96GD4 | CHEMBL2185 |
| Protein Kinase | PTK2 | Focal adhesion kinase 1 | Q05397 | CHEMBL2695 |
| Protein Kinase | ALK | ALK tyrosine kinase receptor | Q9UM73 | CHEMBL4247 |
| Small molecule receptor (family A GPCR) | DRD4 | Dopamine D4 receptor | P21917 | CHEMBL219 |
| Transcription Factor | AHR | Aryl hydrocarbon receptor | P35869 | CHEMBL3201 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
| Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
| Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
| Transcription Factor | STAT6 | Signal transducer and activator of transcription 6 | P42226 | CHEMBL5401 |
| Transferase | FUT7 | Alpha-(1,3)-fucosyltransferase 7 | Q11130 | CHEMBL3596077 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 2.498E-13 | 2.365E-10 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C8, CYP2C9, CYP3A4, NOX4 |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 1.085E-12 | 8.748E-10 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C8, CYP2C9 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 4.012E-12 | 2.818E-09 | ALOX12, ALOX15, ALOX5, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C8, CYP2C9, CYP3A4, XDH |
| MF | GO:0005488; binding | GO:0020037; heme binding | 7.537E-12 | 5.129E-09 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C8, CYP2C9, CYP3A4, MPO, NOX4, SRC |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 2.699E-10 | 1.069E-07 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C8, CYP2C9 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 3.169E-10 | 1.170E-07 | CYP1A2, CYP2C8, CYP2C9, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 4.987E-10 | 1.724E-07 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C8, CYP3A4 |
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 1.003E-09 | 3.119E-07 | CYP1A2, CYP2C19, CYP2C8, CYP2C9, CYP3A4 |
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 1.182E-09 | 3.432E-07 | AR, CA1, CA12, CA13, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9, ESRRA, GLO1, MMP13, MMP2, MMP3, MMP9, TP53 |
| MF | GO:0005488; binding | GO:0005524; ATP binding | 1.416E-09 | 4.004E-07 | ABCC1, ABCG2, AKT1, ALK, AURKB, AXL, CAMK2B, CDK1, CSNK2A1, DAPK1, FLT3, GSK3B, IGF1R, KDR, MET, NEK2, NEK6, NUAK1, PIM1, PKN1, PTK2, PYGL, RECQL, SRC, TP53 |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 4.723E-09 | 1.143E-06 | CYP1A2, CYP2C19, CYP2C9, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0004674; protein serine/threonine kinase activity | 6.505E-08 | 1.221E-05 | AKT1, ALK, AURKB, CAMK2B, CDK1, CSNK2A1, DAPK1, GSK3B, NEK2, NEK6, NUAK1, PIM1, PKN1 |
| BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 1.528E-07 | 2.727E-05 | CYP1A2, CYP2C8, CYP2C9, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0006691; leukotriene metabolic process | 2.018E-07 | 3.380E-05 | ABCC1, ALOX12, ALOX15, ALOX5, PLA2G1B |
| MF | GO:0005488; binding | GO:0051879; Hsp90 protein binding | 2.384E-07 | 3.902E-05 | AHR, CSNK2A1, HIF1A, KDR, MAPT |
| BP | GO:0008152; metabolic process | GO:0018105; peptidyl-serine phosphorylation | 5.476E-07 | 8.338E-05 | AKT1, AURKB, CAMK2B, CDK1, GSK3B, NEK6, PKN1, SRC |
| BP | GO:0008152; metabolic process | GO:0019372; lipoxygenase pathway | 5.545E-07 | 8.385E-05 | ALOX12, ALOX15, ALOX5, HPGD |
| MF | GO:0003824; catalytic activity | GO:0101020; estrogen 16-alpha-hydroxylase activity | 7.603E-07 | 1.068E-04 | CYP1A1, CYP2C8, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0018107; peptidyl-threonine phosphorylation | 1.051E-06 | 1.387E-04 | AKT1, CAMK2B, CDK1, CSNK2A1, GSK3B, PKN1 |
| BP | GO:0008152; metabolic process | GO:0002933; lipid hydroxylation | 1.516E-06 | 1.854E-04 | CYP1A1, CYP2C8, CYP3A4 |
| BP | Unclassified; | GO:0044236; multicellular organism metabolic process | 6.346E-06 | 6.687E-04 | HIF1A, MMP13, MMP2, MMP3, MMP9, PLA2G1B |
| BP | GO:0009987; cellular process | GO:0070301; cellular response to hydrogen peroxide | 6.387E-06 | 6.687E-04 | AKR1B1, AXL, CDK1, CYP1B1, STAT6 |
| BP | GO:0032502; developmental process | GO:0007568; aging | 6.760E-06 | 6.976E-04 | AKT1, AURKB, CDK1, CYP1A1, MPO, NOX4, POLB, TP53 |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 7.771E-27 | 1.692E-22 | CA1, CA12, CA13, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
| MF | GO:0005488; binding | GO:0042802; identical protein binding | 1.379E-05 | 1.328E-03 | ABCG2, AKT1, ALK, CAMK2B, CSNK2A1, DAPK1, DRD4, FLT3, HPGD, IGF1R, KDR, MAPT, MET, MMP9, NFKB1, PYGL, STAT6, TP53, TYR, XDH |
| BP | GO:0009987; cellular process | GO:0048010; vascular endothelial growth factor receptor signaling pathway | 1.448E-05 | 1.389E-03 | AXL, KDR, PIK3R1, PTK2, SRC |
| BP | Unclassified; | GO:0044243; multicellular organismal catabolic process | 1.549E-05 | 1.464E-03 | MMP13, MMP2, MMP3, MMP9, PLA2G1B |
| BP | GO:0009987; cellular process | GO:1903201; regulation of oxidative stress-induced cell death | 1.656E-05 | 1.547E-03 | AKT1, HIF1A, MET, MMP3, TP53 |
| CC | GO:0044464; cell part | GO:0005829; cytosol | 1.776E-05 | 1.645E-03 | AHR, AKR1B1, AKT1, ALDH1A1, ALOX12, ALOX15, ALOX5, AR, AURKB, CA1, CA13, CA2, CA3, CA7, CAMK2B, CDK1, CSNK2A1, FLT3, GLO1, GSK3B, HIF1A, HPGD, HSD17B1, LMNA, MAPT, NEK2, NEK6, NFKB1, PIK3R1, PIM1, PKN1, PLA2G1B, PTK2, PYGL, SRC, STAT6, TP53, TYR, XDH |
| BP | GO:0008152; metabolic process | GO:2001303; lipoxin A4 biosynthetic process | 1.824E-05 | 1.655E-03 | ALOX12, ALOX15 |
| MF | GO:0003824; catalytic activity | GO:0047977; hepoxilin-epoxide hydrolase activity | 1.824E-05 | 1.655E-03 | ALOX12, ALOX15 |
| BP | GO:0008152; metabolic process | GO:0006703; estrogen biosynthetic process | 2.121E-05 | 1.855E-03 | CYP19A1, HSD17B1, HSD17B2 |
| BP | Unclassified; | GO:0044259; multicellular organismal macromolecule metabolic process | 3.438E-05 | 2.786E-03 | HIF1A, MMP13, MMP2, MMP3, MMP9 |
| BP | GO:0009987; cellular process | GO:0090199; regulation of release of cytochrome c from mitochondria | 4.129E-05 | 3.269E-03 | AKT1, LMNA, MMP9, TP53 |
| BP | GO:0008152; metabolic process | GO:2000379; positive regulation of reactive oxygen species metabolic process | 4.281E-05 | 3.365E-03 | AKT1, MAPT, NOX4, TP53, XDH |
| BP | GO:0008152; metabolic process | GO:0038083; peptidyl-tyrosine autophosphorylation | 4.911E-05 | 3.809E-03 | IGF1R, KDR, PTK2, SRC |
| BP | GO:0009987; cellular process | GO:0051897; positive regulation of protein kinase B signaling | 4.929E-05 | 3.809E-03 | AXL, MET, NOX4, PIK3R1, PTK2, SRC |
| MF | GO:0003824; catalytic activity | GO:0008392; arachidonic acid epoxygenase activity | 4.981E-05 | 3.809E-03 | CYP2C19, CYP2C8, CYP2C9 |
| MF | GO:0003824; catalytic activity | GO:0035173; histone kinase activity | 4.981E-05 | 3.809E-03 | AURKB, CDK1, PKN1 |
| BP | GO:0009987; cellular process | GO:0031334; positive regulation of protein complex assembly | 5.193E-05 | 3.954E-03 | ALOX15, GSK3B, MAPT, MET, MMP3, SRC, TP53 |
| BP | Unclassified; | GO:0032846; positive regulation of homeostatic process | 5.341E-05 | 4.038E-03 | AURKB, CA2, CA7, HIF1A, NEK2, NPSR1, PLA2G1B |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 5.457E-05 | 4.070E-03 | CA2, CA7 |
| MF | GO:0003824; catalytic activity | GO:0070576; vitamin D 24-hydroxylase activity | 5.457E-05 | 4.070E-03 | CYP1A1, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0004052; arachidonate 12-lipoxygenase activity | 5.457E-05 | 4.070E-03 | ALOX12, ALOX15 |
| MF | GO:0003824; catalytic activity | GO:0051120; hepoxilin A3 synthase activity | 5.457E-05 | 4.070E-03 | ALOX12, ALOX15 |
| BP | GO:0009987; cellular process | GO:0043065; positive regulation of apoptotic process | 5.676E-05 | 4.204E-03 | AKT1, CYP1B1, DAPK1, GSK3B, HPGD, MAPT, MMP9, NOX4, SRC, TP53, XDH |
| MF | GO:0005488; binding | GO:0046983; protein dimerization activity | 7.909E-05 | 5.557E-03 | ABCG2, AHR, AKT1, AR, AXL, CAMK2B, FLT3, HIF1A, HPGD, MAPT, NFKB1, PIK3R1, PYGL, TP53, TYR, XDH |
| BP | GO:0022610; biological adhesion | GO:0001952; regulation of cell-matrix adhesion | 8.163E-05 | 5.697E-03 | GSK3B, KDR, PIK3R1, PTK2, SRC |
| BP | GO:0009987; cellular process | GO:2001237; negative regulation of extrinsic apoptotic signaling pathway | 8.163E-05 | 5.697E-03 | AKT1, AR, DAPK1, LMNA, SRC |
| BP | GO:0002376; immune system process | GO:0048534; hematopoietic or lymphoid organ development | 8.312E-05 | 5.783E-03 | FLT3, HIF1A, KDR, PKN1, POLB, TYR |
| BP | GO:0032502; developmental process | GO:0051094; positive regulation of developmental process | 8.364E-05 | 5.800E-03 | AKT1, ALOX12, AR, AXL, CA2, CAMK2B, CDK1, CYP1B1, HIF1A, KDR, LMNA, MAPT, NFKB1, PIM1, SRC, STAT6 |
| BP | GO:0009987; cellular process | GO:0071456; cellular response to hypoxia | 8.546E-05 | 5.908E-03 | AKT1, HIF1A, LMNA, SRC, TP53 |
| BP | GO:0008152; metabolic process | GO:1901575; organic substance catabolic process | 8.932E-05 | 6.143E-03 | AKT1, ALDH1A1, AURKB, BACE1, CDK1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP3A4, FUT7, GSK3B, HSD17B10, MAOA, PLA2G1B, PYGL, TP53, XDH |
| BP | GO:0050896; response to stimulus | GO:0055093; response to hyperoxia | 9.622E-05 | 6.568E-03 | CYP1A1, POLB, TP53 |
| MF | GO:0003824; catalytic activity | GO:0009055; electron transfer activity | 1.022E-04 | 6.878E-03 | AKR1B1, CYP19A1, CYP1A2, NOX4, XDH |
| CC | GO:0016020; membrane | GO:0005886; plasma membrane | 1.023E-04 | 6.878E-03 | ABCC1, ABCG2, AKT1, ALK, ALOX12, ALOX15, AR, AXL, BACE1, CA12, CA14, CA2, CA4, CA9, CAMK2B, CSNK2A1, CXCR1, DAPK1, DRD4, FLT3, GLO1, GSK3B, HSD17B10, IGF1R, KDR, MAPT, MET, MMP2, NPSR1, PIK3R1, PIM1, PKN1, PTK2, SRC, TDP1 |
| BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 1.088E-04 | 7.204E-03 | CYP1A1, CYP1A2 |
| MF | GO:0005488; binding | GO:0005497; androgen binding | 1.088E-04 | 7.204E-03 | ALDH1A1, AR |
| BP | GO:0008152; metabolic process | GO:0044283; small molecule biosynthetic process | 1.107E-04 | 7.283E-03 | AKR1B1, ALOX12, ALOX15, ALOX5, CYP19A1, CYP1A1, CYP3A4, MPO, PLA2G1B |
| BP | GO:0008283; cell proliferation | GO:1904707; positive regulation of vascular smooth muscle cell proliferation | 1.111E-04 | 7.284E-03 | HPGD, MMP2, MMP9 |
| BP | GO:0032501; multicellular organismal process | GO:2000026; regulation of multicellular organismal development | 1.263E-04 | 8.140E-03 | AKT1, ALOX12, AR, AXL, CA2, CAMK2B, CDK1, CTDSP1, CYP1B1, ESRRA, GSK3B, HIF1A, KDR, MAPT, PIK3R1, PIM1, PTK2, SRC, STAT6, XDH |
| BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 1.273E-04 | 8.179E-03 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0009987; cellular process | GO:0071407; cellular response to organic cyclic compound | 1.323E-04 | 8.475E-03 | AKT1, AR, CYP1A1, CYP1B1, FLT3, NFKB1, NOX4, SRC |
| BP | GO:0009987; cellular process | GO:0071345; cellular response to cytokine stimulus | 1.430E-04 | 9.089E-03 | AKT1, ALOX15, AXL, DAPK1, FLT3, GSK3B, HIF1A, NFKB1 |
| BP | GO:0065007; biological regulation | GO:0048872; homeostasis of number of cells | 1.432E-04 | 9.089E-03 | AXL, FLT3, HIF1A, PKN1, POLB |
| BP | GO:0050896; response to stimulus | GO:0045471; response to ethanol | 1.432E-04 | 9.089E-03 | CA3, CDK1, HPGD, POLB, TP53 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 3.264E-19 | 1.184E-15 | CA1, CA12, CA13, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 2.552E-18 | 6.173E-15 | CA1, CA12, CA13, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 6.917E-26 | 1.224E-23 | CA12; CA1; CA3; CA5B; CA2; CA5A; CA4; CA7; CA6; CA9; CA14; CA13 |
| hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 4.447E-11 | 2.624E-09 | CAMK2B; SRC; MMP2; KDR; AKT1; PIK3R1; TP53; HIF1A; MMP9; MET; PTK2; IGF1R |
| hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 8.958E-10 | 3.964E-08 | GSK3B; FLT3; DAPK1; MMP2; PIK3R1; HIF1A; MMP9; NFKB1; PTK2; IGF1R; AR; AKT1; MET; TP53 |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 2.374E-11 | 2.101E-09 | CYP2C9; CYP2C8; PLA2G1B; CYP1A2; ALOX15; CYP3A4; CYP2C19 |
| hsa04913 | Ovarian steroidogenesis_Homo sapiens_hsa04913 | 1.416E-09 | 5.014E-08 | HSD17B1; ALOX5; HSD17B2; CYP1A1; CYP1B1; CYP19A1; IGF1R |
| hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 6.701E-09 | 1.483E-07 | CYP2C9; CYP2C8; PLA2G1B; ALOX5; ALOX15; ALOX12; CYP2C19 |
| hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 2.207E-08 | 4.340E-07 | PLA2G1B; MAOA; ALOX15; AKR1B1; ALOX12; PYGL; CYP2C19; CYP3A4; TYR; CYP19A1; HSD17B10; CYP2C9; CYP2C8; FUT7; HSD17B1; ALOX5; HSD17B2; CYP1A2; ALDH1A1; CYP1A1; XDH |
| hsa05202 | Transcriptional misregulation in cancer_Homo sapiens_hsa05202 | 3.741E-09 | 1.050E-07 | HPGD; FLT3; MMP3; TP53; MPO; MMP9; MET; NFKB1; PTK2; IGF1R |
| hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 4.152E-09 | 1.050E-07 | HSD17B1; CYP1A2; HSD17B2; CYP1A1; CYP1B1; CYP3A4; CYP19A1 |
| hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 8.581E-08 | 1.381E-06 | GSK3B; AR; AKT1; PIK3R1; TP53; NFKB1; IGF1R |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 4.846E-08 | 8.578E-07 | CYP2C9; CYP2C8; CYP1A2; CYP1A1; CYP1B1; CYP3A4; CYP2C19 |
| hsa04151 | PI3K-Akt signaling pathway_Homo sapiens_hsa04151 | 1.469E-06 | 1.530E-05 | GSK3B; KDR; AKT1; PIK3R1; PKN1; TP53; MET; PTK2; NFKB1; IGF1R |
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 4.179E-07 | 4.932E-06 | CYP2C9; CYP2C8; MAOA; ALOX5; ALOX15; ALOX12; CYP2C19 |
| hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 3.467E-07 | 4.720E-06 | FLT3; AKT1; PIK3R1; TP53; MET; HIF1A |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 2.888E-07 | 4.260E-06 | CYP2C9; CYP2C8; CYP1A2; ALDH1A1; CYP1A1; CYP3A4 |
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 4.137E-07 | 4.932E-06 | CYP2C9; CYP2C8; MAOA; CYP1A2; CYP3A4; CYP2C19 |
| hsa04510 | Focal adhesion_Homo sapiens_hsa04510 | 1.944E-06 | 1.811E-05 | GSK3B; SRC; KDR; AKT1; PIK3R1; MET; PTK2; IGF1R |
| hsa05161 | Hepatitis B_Homo sapiens_hsa05161 | 2.498E-06 | 2.211E-05 | SRC; AKT1; STAT6; PIK3R1; TP53; MMP9; NFKB1 |
| hsa04012 | ErbB signaling pathway_Homo sapiens_hsa04012 | 1.642E-06 | 1.615E-05 | CAMK2B; GSK3B; SRC; AKT1; PIK3R1; PTK2 |
| hsa05219 | Bladder cancer_Homo sapiens_hsa05219 | 7.261E-07 | 8.033E-06 | DAPK1; SRC; MMP2; MMP9; TP53 |
| hsa04066 | HIF-1 signaling pathway_Homo sapiens_hsa04066 | 4.411E-06 | 3.549E-05 | CAMK2B; AKT1; PIK3R1; HIF1A; NFKB1; IGF1R |
| hsa05221 | Acute myeloid leukemia_Homo sapiens_hsa05221 | 3.852E-06 | 3.246E-05 | FLT3; PIM1; AKT1; PIK3R1; NFKB1 |
| hsa05214 | Glioma_Homo sapiens_hsa05214 | 7.403E-06 | 5.460E-05 | CAMK2B; AKT1; PIK3R1; TP53; IGF1R |
| hsa04370 | VEGF signaling pathway_Homo sapiens_hsa04370 | 5.402E-06 | 4.157E-05 | SRC; KDR; AKT1; PIK3R1; PTK2 |
| hsa04919 | Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | 9.674E-06 | 6.849E-05 | GSK3B; SRC; AKT1; PIK3R1; TP53; HIF1A |
| hsa04722 | Neurotrophin signaling pathway_Homo sapiens_hsa04722 | 1.065E-05 | 7.253E-05 | CAMK2B; GSK3B; AKT1; PIK3R1; TP53; NFKB1 |
| hsa04062 | Chemokine signaling pathway_Homo sapiens_hsa04062 | 1.273E-05 | 7.739E-05 | GSK3B; CXCR1; SRC; AKT1; PIK3R1; NFKB1; PTK2 |
| hsa05169 | Epstein-Barr virus infection_Homo sapiens_hsa05169 | 2.096E-05 | 1.197E-04 | GSK3B; CSNK2A1; CDK1; AKT1; PIK3R1; TP53; NFKB1 |
| hsa05218 | Melanoma_Homo sapiens_hsa05218 | 1.144E-05 | 7.502E-05 | AKT1; PIK3R1; TP53; MET; IGF1R |
| hsa04917 | Prolactin signaling pathway_Homo sapiens_hsa04917 | 1.226E-05 | 7.739E-05 | GSK3B; SRC; AKT1; PIK3R1; NFKB1 |
| hsa05162 | Measles_Homo sapiens_hsa05162 | 2.174E-05 | 1.203E-04 | GSK3B; CSNK2A1; AKT1; PIK3R1; TP53; NFKB1 |
| hsa04014 | Ras signaling pathway_Homo sapiens_hsa04014 | 4.418E-05 | 2.202E-04 | PLA2G1B; KDR; AKT1; PIK3R1; MET; NFKB1; IGF1R |
| hsa04933 | AGE-RAGE signaling pathway in diabetic complications_Homo sapiens_hsa04933 | 6.317E-05 | 2.911E-04 | MMP2; PIM1; AKT1; PIK3R1; NFKB1 |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 1.312E-05 | 7.739E-05 | CYP2C9; CYP1A2; CYP1A1; CYP1B1; CYP3A4 |
| hsa04211 | Longevity regulating pathway - mammal_Homo sapiens_hsa04211 | 4.478E-05 | 2.202E-04 | AKT1; PIK3R1; TP53; NFKB1; IGF1R |
| hsa05222 | Small cell lung cancer_Homo sapiens_hsa05222 | 2.916E-05 | 1.518E-04 | AKT1; PIK3R1; TP53; NFKB1; PTK2 |
| hsa04915 | Estrogen signaling pathway_Homo sapiens_hsa04915 | 5.741E-05 | 2.747E-04 | SRC; MMP2; AKT1; PIK3R1; MMP9 |
| hsa04668 | TNF signaling pathway_Homo sapiens_hsa04668 | 9.481E-05 | 3.995E-04 | MMP3; AKT1; PIK3R1; MMP9; NFKB1 |
| hsa04931 | Insulin resistance_Homo sapiens_hsa04931 | 9.079E-05 | 3.920E-04 | GSK3B; AKT1; PIK3R1; PYGL; NFKB1 |
| hsa05203 | Viral carcinogenesis_Homo sapiens_hsa05203 | 2.111E-04 | 7.474E-04 | POLB; SRC; CDK1; PIK3R1; TP53; NFKB1 |
| hsa04071 | Sphingolipid signaling pathway_Homo sapiens_hsa04071 | 1.429E-04 | 5.749E-04 | ABCC1; AKT1; PIK3R1; TP53; NFKB1 |
| hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 2.350E-04 | 7.912E-04 | ABCC1; PIM1; CYP1B1; TP53; MMP9; MET; NFKB1 |
| hsa04728 | Dopaminergic synapse_Homo sapiens_hsa04728 | 2.005E-04 | 7.242E-04 | CAMK2B; GSK3B; MAOA; AKT1; DRD4 |
| hsa04015 | Rap1 signaling pathway_Homo sapiens_hsa04015 | 2.466E-04 | 7.937E-04 | SRC; KDR; AKT1; PIK3R1; MET; IGF1R |
| hsa05160 | Hepatitis C_Homo sapiens_hsa05160 | 2.311E-04 | 7.912E-04 | GSK3B; AKT1; PIK3R1; TP53; NFKB1 |
| hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 2.931E-04 | 9.102E-04 | LMNA; AKT1; PIK3R1; TP53; NFKB1 |
| hsa05223 | Non-small cell lung cancer_Homo sapiens_hsa05223 | 8.593E-05 | 3.803E-04 | ALK; AKT1; PIK3R1; TP53 |
| hsa05213 | Endometrial cancer_Homo sapiens_hsa05213 | 6.414E-05 | 2.911E-04 | GSK3B; AKT1; PIK3R1; TP53 |
| hsa05166 | HTLV-I infection_Homo sapiens_hsa05166 | 7.158E-04 | 2.147E-03 | POLB; GSK3B; AKT1; PIK3R1; TP53; NFKB1 |
| hsa05210 | Colorectal cancer_Homo sapiens_hsa05210 | 1.281E-04 | 5.272E-04 | GSK3B; AKT1; PIK3R1; TP53 |
| hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 1.634E-04 | 6.287E-04 | AKT1; PIK3R1; TP53; NFKB1 |
| hsa05211 | Renal cell carcinoma_Homo sapiens_hsa05211 | 1.634E-04 | 6.287E-04 | AKT1; PIK3R1; MET; HIF1A |
| hsa04750 | Inflammatory mediator regulation of TRP channels_Homo sapiens_hsa04750 | 7.406E-04 | 2.149E-03 | CAMK2B; SRC; ALOX12; PIK3R1 |
| hsa04662 | B cell receptor signaling pathway_Homo sapiens_hsa04662 | 2.414E-04 | 7.912E-04 | GSK3B; AKT1; PIK3R1; NFKB1 |
| hsa04914 | Progesterone-mediated oocyte maturation_Homo sapiens_hsa04914 | 7.406E-04 | 2.149E-03 | CDK1; AKT1; PIK3R1; IGF1R |
| hsa05120 | Epithelial cell signaling in Helicobacter pylori infection_Homo sapiens_hsa05120 | 1.835E-04 | 6.766E-04 | CXCR1; SRC; MET; NFKB1 |
| hsa05220 | Chronic myeloid leukemia_Homo sapiens_hsa05220 | 2.414E-04 | 7.912E-04 | AKT1; PIK3R1; TP53; NFKB1 |
| hsa00380 | Tryptophan metabolism_Homo sapiens_hsa00380 | 2.249E-05 | 1.206E-04 | MAOA; CYP1A2; CYP1A1; CYP1B1 |
| hsa04660 | T cell receptor signaling pathway_Homo sapiens_hsa04660 | 9.252E-04 | 2.641E-03 | GSK3B; AKT1; PIK3R1; NFKB1 |
| hsa05145 | Toxoplasmosis_Homo sapiens_hsa05145 | 1.478E-03 | 4.087E-03 | ALOX5; AKT1; PIK3R1; NFKB1 |
| hsa04114 | Oocyte meiosis_Homo sapiens_hsa04114 | 1.721E-03 | 4.687E-03 | CAMK2B; AR; CDK1; IGF1R |
| hsa04144 | Endocytosis_Homo sapiens_hsa04144 | 4.477E-03 | 1.057E-02 | CXCR1; SRC; KDR; MET; IGF1R |
| hsa04550 | Signaling pathways regulating pluripotency of stem cells_Homo sapiens_hsa04550 | 2.900E-03 | 7.334E-03 | GSK3B; AKT1; PIK3R1; IGF1R |
| hsa04310 | Wnt signaling pathway_Homo sapiens_hsa04310 | 2.900E-03 | 7.334E-03 | CAMK2B; GSK3B; CSNK2A1; TP53 |
| hsa04910 | Insulin signaling pathway_Homo sapiens_hsa04910 | 2.685E-03 | 6.990E-03 | GSK3B; AKT1; PIK3R1; PYGL |
| hsa04932 | Non-alcoholic fatty liver disease (NAFLD)_Homo sapiens_hsa04932 | 3.615E-03 | 8.887E-03 | GSK3B; AKT1; PIK3R1; NFKB1 |
| hsa04670 | Leukocyte transendothelial migration_Homo sapiens_hsa04670 | 1.478E-03 | 4.087E-03 | MMP2; PIK3R1; MMP9; PTK2 |
| hsa04630 | Jak-STAT signaling pathway_Homo sapiens_hsa04630 | 4.247E-03 | 1.016E-02 | PIM1; AKT1; STAT6; PIK3R1 |
| hsa04520 | Adherens junction_Homo sapiens_hsa04520 | 2.544E-04 | 8.040E-04 | CSNK2A1; SRC; MET; IGF1R |
| hsa05100 | Bacterial invasion of epithelial cells_Homo sapiens_hsa05100 | 3.114E-04 | 9.503E-04 | SRC; PIK3R1; MET; PTK2 |
| hsa05164 | Influenza A_Homo sapiens_hsa05164 | 6.085E-03 | 1.399E-02 | GSK3B; AKT1; PIK3R1; NFKB1 |
| hsa05010 | Alzheimer's disease_Homo sapiens_hsa05010 | 5.275E-03 | 1.228E-02 | BACE1; GSK3B; MAPT; HSD17B10 |
| hsa05152 | Tuberculosis_Homo sapiens_hsa05152 | 6.457E-03 | 1.447E-02 | CAMK2B; SRC; AKT1; NFKB1 |
| hsa05168 | Herpes simplex infection_Homo sapiens_hsa05168 | 7.381E-03 | 1.633E-02 | CSNK2A1; CDK1; TP53; NFKB1 |
| hsa04024 | cAMP signaling pathway_Homo sapiens_hsa04024 | 9.484E-03 | 1.929E-02 | CAMK2B; AKT1; PIK3R1; NFKB1 |
| hsa04912 | GnRH signaling pathway_Homo sapiens_hsa04912 | 6.440E-03 | 1.447E-02 | CAMK2B; SRC; MMP2 |
| hsa04916 | Melanogenesis_Homo sapiens_hsa04916 | 8.346E-03 | 1.802E-02 | CAMK2B; GSK3B; TYR |
| hsa05146 | Amoebiasis_Homo sapiens_hsa05146 | 8.346E-03 | 1.802E-02 | PIK3R1; NFKB1; PTK2 |
| hsa05231 | Choline metabolism in cancer_Homo sapiens_hsa05231 | 8.576E-03 | 1.807E-02 | AKT1; PIK3R1; HIF1A |
| hsa04611 | Platelet activation_Homo sapiens_hsa04611 | 1.428E-02 | 2.797E-02 | SRC; AKT1; PIK3R1 |
| hsa04922 | Glucagon signaling pathway_Homo sapiens_hsa04922 | 8.576E-03 | 1.807E-02 | CAMK2B; AKT1; PYGL |
| hsa04725 | Cholinergic synapse_Homo sapiens_hsa04725 | 1.108E-02 | 2.204E-02 | CAMK2B; AKT1; PIK3R1 |
| hsa04010 | MAPK signaling pathway_Homo sapiens_hsa04010 | 2.165E-02 | 3.794E-02 | AKT1; MAPT; TP53; NFKB1 |
| hsa04620 | Toll-like receptor signaling pathway_Homo sapiens_hsa04620 | 9.783E-03 | 1.968E-02 | AKT1; PIK3R1; NFKB1 |
| hsa05142 | Chagas disease (American trypanosomiasis)_Homo sapiens_hsa05142 | 9.289E-03 | 1.912E-02 | AKT1; PIK3R1; NFKB1 |
| hsa04152 | AMPK signaling pathway_Homo sapiens_hsa04152 | 1.491E-02 | 2.826E-02 | AKT1; PIK3R1; IGF1R |
| hsa04060 | Cytokine-cytokine receptor interaction_Homo sapiens_hsa04060 | 2.450E-02 | 4.092E-02 | CXCR1; FLT3; KDR; MET |
| hsa04110 | Cell cycle_Homo sapiens_hsa04110 | 1.491E-02 | 2.826E-02 | GSK3B; CDK1; TP53 |
| hsa04380 | Osteoclast differentiation_Homo sapiens_hsa04380 | 1.760E-02 | 3.186E-02 | AKT1; PIK3R1; NFKB1 |
| hsa04530 | Tight junction_Homo sapiens_hsa04530 | 2.015E-02 | 3.567E-02 | CSNK2A1; SRC; AKT1 |
| hsa04068 | FoxO signaling pathway_Homo sapiens_hsa04068 | 1.795E-02 | 3.209E-02 | AKT1; PIK3R1; IGF1R |
| hsa04072 | Phospholipase D signaling pathway_Homo sapiens_hsa04072 | 2.210E-02 | 3.797E-02 | CXCR1; AKT1; PIK3R1 |
| hsa04360 | Axon guidance_Homo sapiens_hsa04360 | 1.589E-02 | 2.930E-02 | GSK3B; MET; PTK2 |
| hsa04261 | Adrenergic signaling in cardiomyocytes_Homo sapiens_hsa04261 | 2.373E-02 | 3.999E-02 | CAMK2B; AKT1; PIK3R1 |
| hsa04921 | Oxytocin signaling pathway_Homo sapiens_hsa04921 | 2.807E-02 | 4.643E-02 | CAMK2B; SRC; PIK3R1 |
| hsa04213 | Longevity regulating pathway - multiple species_Homo sapiens_hsa04213 | 2.393E-03 | 6.321E-03 | AKT1; PIK3R1; IGF1R |
| hsa04150 | mTOR signaling pathway_Homo sapiens_hsa04150 | 1.989E-03 | 5.334E-03 | AKT1; PIK3R1; HIF1A |
| hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 3.215E-03 | 8.014E-03 | CA2; CYP3A4; ABCG2 |
| hsa05131 | Shigellosis_Homo sapiens_hsa05131 | 2.990E-02 | 4.855E-02 | SRC; NFKB1 |
| hsa05321 | Inflammatory bowel disease (IBD)_Homo sapiens_hsa05321 | 2.990E-02 | 4.855E-02 | STAT6; NFKB1 |
| hsa04923 | Regulation of lipolysis in adipocytes_Homo sapiens_hsa04923 | 2.267E-02 | 3.858E-02 | AKT1; PIK3R1 |
| hsa05217 | Basal cell carcinoma_Homo sapiens_hsa05217 | 2.192E-02 | 3.797E-02 | GSK3B; TP53 |
| hsa05030 | Cocaine addiction_Homo sapiens_hsa05030 | 1.764E-02 | 3.186E-02 | MAOA; NFKB1 |
| hsa04973 | Carbohydrate digestion and absorption_Homo sapiens_hsa04973 | 1.501E-02 | 2.826E-02 | AKT1; PIK3R1 |
| hsa02010 | ABC transporters_Homo sapiens_hsa02010 | 1.438E-02 | 2.797E-02 | ABCC1; ABCG2 |
| hsa00983 | Drug metabolism - other enzymes_Homo sapiens_hsa00983 | 1.565E-02 | 2.916E-02 | CYP3A4; XDH |
| hsa00350 | Tyrosine metabolism_Homo sapiens_hsa00350 | 9.264E-03 | 1.912E-02 | MAOA; TYR |
| hsa04964 | Proximal tubule bicarbonate reclamation_Homo sapiens_hsa04964 | 4.068E-03 | 9.864E-03 | CA2; CA4 |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 1.688E-04 | 6.356E-04 | CYP1A2; XDH |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3 |
| J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3 |
| C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | MET |
| K00-K95: Diseases of the digestive system | Alcoholic hepatitis | K70.1 | AR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | MAOA |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Erectile dysfunction | F52.2, N48.4 | DRD4 |
| C00-D49: Neoplasms | Advanced malignancies | C00-C96 | KDR |
| C00-D49: Neoplasms | Advanced prostate cancer | C61 | AR |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1 |
| A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | ALOX5 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | MET |
| C00-D49: Neoplasms | Gastric cancer | C16 | KDR; KDR |
| L00-L99: Diseases of the skin and subcutaneous tissue | Contact dermatitis | L23, L24, L25 | PLA2G1B |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | TP53; FLT3; MMP9; IGF1R; KDR |
| C00-D49: Neoplasms | Colon cancer | C50 | FLT3 |
| C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | MET; IGF1R; KDR |
| NA: NA | Hematopoietic stem cell transplantation | NA | FLT3 |
| C00-D49: Neoplasms | Hematologic malignancies | C81-C86 | AKT1 |
| NA: NA | GIST | NA | FLT3 |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | AXL; MET; IGF1R; IGF1R; KDR |
| L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | TYR; MAOA |
| C00-D49: Neoplasms | Fallopian tube cancer | C57.0, D28.2 | KDR |
| C00-D49: Neoplasms | Female androgenresponsive recurrent mammary cancer | C50 | AR |
| Z00-Z99: Factors influencing health status and contact with health services | Contraception | Z30 | AR |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | AR; XDH |
| C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | AR; IGF1R |
| C00-D49: Neoplasms | Hormone refractory prostate cancer | C61 | AR |
| C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1 |
| NA: NA | HIV infections | NA | AHR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | DRD4; ESRRA |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | TP53; TP53; FLT3; FLT3; AURKB |
| C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3 |
| C00-D49: Neoplasms | Lung cancer | C33-C34 | MMP2 |
| K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | MET |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | AKT1; HIF1A; CA9 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Growth failure | R62.8 | IGF1R |
| H00-H59: Diseases of the eye and adnexa | Graves' ophthalmopathy | H06.2 | IGF1R |
| C00-D49: Neoplasms | Renal cancer | C64 | CA9; KDR |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | MMP2; KDR |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | MAOA |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | TP53; PTK2 |
| A00-B99: Certain infectious and parasitic diseases | Leishmaniasis | B55.0 | PLA2G1B |
| C00-D49: Neoplasms | Leukemia | C90-C95 | AKT1; FLT3 |
| C00-D49: Neoplasms | Liver cancer | C22 | IGF1R; KDR |
| C00-D49: Neoplasms | Thyroid cancer | C73 | KDR |
| A00-B99: Certain infectious and parasitic diseases | HCV infection | B17.1, B18.2 | MMP3 |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | TP53; AKR1B1; KDR; KDR |
| I00-I99: Diseases of the circulatory system | Heart disease | I00-I52 | MET |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA2; CA4 |
| C00-D49: Neoplasms | Metastatic breast cancer | C50 | KDR |
| C00-D49: Neoplasms | Squamous cell cancer of head and neck | NA | KDR |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | ALOX5; TYR; AKR1B1; MMP3; CAMK2B; PLA2G1B; ESRRA |
| J00-J99: Diseases of the respiratory system | Rhinitis | J00, J30, J31.0 | ALOX5 |
| I00-I99: Diseases of the circulatory system | Ischemia | I99.8 | SRC |
| I00-I99: Diseases of the circulatory system | Ischemic stroke | I61-I63 | MMP3 |
| K00-K95: Diseases of the digestive system | Gastrointestinal disease | K00-K93 | ESRRA |
| H00-H59: Diseases of the eye and adnexa | Corneal ulcers | H16.0 | MMP3 |
| I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | ALOX5 |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | ALOX5; MPO; MMP13; PLA2G1B |
| L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory and pruritic manifestations of moderate to severe corticosteroid-responsive dermatoses of the scalp | L20-L30 | PLA2G1B |
| E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | ALOX5 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory and pruritic manifestations of corticosteroid responsive dermatoses | L20-L30 | PLA2G1B |
| C00-D49: Neoplasms | Bladder cancer | C67 | AR; CYP19A1 |
| A00-B99: Certain infectious and parasitic diseases | Visceral leishmaniasis | B55.0 | PLA2G1B |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | CA1; CA1; AKR1B1 |
| C00-D49: Neoplasms | Glioma | C71 | KDR |
| C00-D49: Neoplasms | Gliosarcoma | NA | FLT3 |
| C00-D49: Neoplasms | Glioblastoma | NA | FLT3 |
| C00-D49: Neoplasms | Glioblastoma multiforme | C71 | SRC |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | XDH; AKR1B1; ABCC1; ABCC1 |
| I00-I99: Diseases of the circulatory system | Angiogenesis disorder | I00-I99 | KDR |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | ALOX5; ESRRA |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis in post-menopausal women | M80-M81 | AR |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriatic disorder | L40 | IGF1R |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychotic disorders | F20-F29 | DRD4 |
| C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3 |
| C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | KDR |
| C00-D49: Neoplasms | Metastatic HER2-negative gastric cancer | NA | MET |
| C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | KDR |
| C00-D49: Neoplasms | Metastatic prostate cancer | C61 | AR |
| N00-N99: Diseases of the genitourinary system | Prostate hyperplasia | N40 | AR |
| L00-L99: Diseases of the skin and subcutaneous tissue | Pruritus | L29 | ALOX5; PLA2G1B |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatological disease | L00-L99 | AR; ESRRA |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Endocrine disease | E00-E35 | AR |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | ALOX5; FLT3 |
| C00-D49: Neoplasms | Prostate cancer | C61 | AR; AR; FLT3 |
| N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1 |
| I00-I99: Diseases of the circulatory system | Myocardial infarction | I21, I22 | MMP3 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Myocardial reperfusion injury | T86.4 | AKT1 |
| C00-D49: Neoplasms | Metastasis | C00-C97 | AXL |
| C00-D49: Neoplasms | Mesothelioma | C45 | PTK2 |
| C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | AR; KDR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | ALOX5; PLA2G1B |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | NFKB1 |
| J00-J99: Diseases of the respiratory system | Respiratory disease | J00-J99 | ALOX5 |
| I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53 |
| C00-D49: Neoplasms | Renal cell carcinoma | NA | MMP2; KDR; KDR |
| A00-B99: Certain infectious and parasitic diseases | Lymphatic filariasis | B74 | ALOX5 |
| C00-D49: Neoplasms | Advanced renal cell carcinoma | C64 | KDR; KDR |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | MAOA |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricaemia in gout | E79.0, M10 | XDH |
| C00-D49: Neoplasms | Melanoma | C43 | TYR; KDR; KDR |
| L00-L99: Diseases of the skin and subcutaneous tissue | Melasma | L81.1 | TYR |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | AR; KDR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | ESRRA |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | MAOA; MAOA |
| E00-E89: Endocrine, nutritional and metabolic diseases | Male hormonal deficiencies | E20-E35 | AR |
| NA: NA | Male hypogonadism | NA | AR |
| C00-D49: Neoplasms | Malignant adrenal gland cancer | C74.0 | IGF1R |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | ALOX5; PLA2G1B; ABCC1; ESRRA |
| H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53 |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | MAPT |
| L00-L99: Diseases of the skin and subcutaneous tissue | Atopic dermatitis | L00-L99 | ALOX5 |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | CYP2C9 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Nerve injury | T14.4 | PLA2G1B |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; CA4 |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | TP53; SRC; AURKB |
| K00-K95: Diseases of the digestive system | Chemotherapy-induced mucositis | K12.3 | MET |
| H00-H59: Diseases of the eye and adnexa | Choroidal neovascularisation | H35 | ESRRA |
| I00-I99: Diseases of the circulatory system | Arteriosclerosis | I70 | PLA2G1B |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | ALOX5; ALOX5; PLA2G1B; ESRRA |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | ALOX5 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | ALOX5; MMP3; MMP2; MMP13 |
| C00-D49: Neoplasms | Breast cancer | C50 | AR; CYP19A1; FLT3; FLT3; CA9; CDK1; IGF1R; KDR; KDR; KDR |
| NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3 |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | ALOX5; MPO |
| C00-D49: Neoplasms | Chronic myelogenous leukaemia | C92.1 | SRC |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | AR; SRC |
| C00-D49: Neoplasms | Ovarian cancer | C56 | MMP2; KDR; KDR; KDR; KDR |
| C00-D49: Neoplasms | CLL | NA | FLT3 |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | MAPT |
| C00-D49: Neoplasms | Gastrointestinal cancers | C15-C26 | KDR |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | CA1 |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | MPO; MAOA |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | AR; CDK1; MMP13; IGF1R |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | AKT1; FLT3; MMP2; KDR |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | NPSR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | AKR1B1; GSK3B |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | MAOA |
| E00-E89: Endocrine, nutritional and metabolic diseases | Testosterone deficiency | E29.1 | AR |
| C00-D49: Neoplasms | Biliary cancer | C22, C24 | KDR |
| C00-D49: Neoplasms | Medullary thyroid cancer | C73 | KDR |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | AKT1; HIF1A; TP53; FLT3; CA9; MMP9; SRC; MET; MMP2; IGF1R; KDR; KDR; KDR; PTK2; AURKB |
| E00-E89: Endocrine, nutritional and metabolic diseases | Cystic fibrosis | E84 | AR |
| C00-D49: Neoplasms | Cutaneous Melanoma | C43-C44 | KDR |
| I00-I99: Diseases of the circulatory system | Stroke | I61-I63, I80-I82 | MMP9 |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | SRC |
| G00-G99: Diseases of the nervous system G00-G99 | Encephalopathy | G93.4 | XDH |
| C00-D49: Neoplasms | Osteosarcoma | C40-C41 | SRC; GSK3B |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cachexia | R64 | AR; ESRRA |
| C00-D49: Neoplasms | Cancer | C00-C96 | AR; PIM1; AKT1; HIF1A; TP53; CA1; FLT3; FLT3; CA9; CDK1; MMP9; NFKB1; SRC; MET; MMP2; IGF1R; KDR; GSK3B; PTK2; CSNK2A1 |
| C00-D49: Neoplasms | Advanced breast cancer | C50 | CYP19A1; SRC |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1 |
| C00-D49: Neoplasms | Castration-resistant prostate cancer | C61 | AR |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | MAOA; GSK3B; MAPT |
| K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | MMP9 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CYP3A4; MAOA; CAMK2B |
| NA: NA | Edema | NA | CA2 |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | MAPT |
| G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | MPO |
| C00-D49: Neoplasms | Multiple myeloma | C90 | AHR; SRC; IGF1R |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Muscle atrophy | M62.5 | AR |
| G00-G99: Diseases of the nervous system G00-G99 | Motor neurone disease | G12.2 | IGF1R |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricemia | E79.0 | XDH |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypogonadism | E23.0, E28.3, E29.1 | AR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2 |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; CA1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mood disorder | F30-F39 | MAOA |
| A00-B99: Certain infectious and parasitic diseases | Infections disease | A00-B99 | MPO |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | AR; AR; MMP2; ESRRA |
| C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Alopecia | L65.9 | AR |
| J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | PLA2G1B; ESRRA |
| C00-D49: Neoplasms | AML | NA | FLT3; KDR |
| C00-D49: Neoplasms | Peritoneal cavity cancer | NA | KDR |